RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment
recent articles
Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx...
OptraSCAN: AI-powered digital pathology solution for AFB detection & bacillary grading at scale to support treatment response assessment and follow-up workflows. SAN JOSE, CA, UNITED STATES, February 5, 2026 /EINPresswire.com/...
Proscia: 100% of customers interviewed would buy again, citing trust for primary diagnosis at scale and a partnership they can count on PHILADELPHIA – February 4, 2026 – Proscia®, a software company advancing digital pathology for...
February 2, 2026 at 10:00 a.m. EET. Aiforia Technologies Plc today announced the launch of a new clinical AI solution for gastric cancer diagnostics. This solution is CE-IVD marked under the IVDR. Aiforia® Gastric Cancer AI application is...
From the Proscia blog: Many health systems and academic medical centers (AMCs) have invested heavily in Epic Beaker as the backbone of their clinical, operational, and financial workflows. When institutions run (or plan to run) Epic as their...
Indica Labs: Learn the fundamentals of the HALO GraphQL API and how to design, develop, and implement time-saving automations Designing and Developing Automated Solutions Using the HALO GraphQL API Date: 19 February...
